Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID
PEPN2121
Disease (Sub Disease)
Multiple tumour types
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Sponsor
National Cancer Institute (NCI)
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months and older  
International registry ID's
NCT05286801
Back to Registry
Study Title A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID PEPN2121
Disease (Sub Disease) Multiple tumour types
Diagnosis Stage Newly diagnosed
Relapsed/Refractory
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT05286801
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Months and older  
International registry ID's NCT05286801